Inhaled Nintedanib (AP02) for the Treatment of IPF: Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses to Healthy Subjects and IPF Patients

nintedanib inhaled (AP02) - Avalyn Pharma

Michelle Palacios, PhD; Mark Surber, PhD; Stephen Pham, PhD; Felix Woodhead, MD, PhD; Deepthi Nair, MS

Feb 24, 2025